Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

Maria Rosaria Valerio; Vittorio Gebbia; null Ciccarese; null Clivio; Carlo Putzu; null Giovanardi; null Cagossi; null Gambaro; null Scognamiglio; Enrico De Conciliis; null Montagna; Vittorio Gebbia; Alfredo Butera; null Toniolo; null Ferzi; Paolo Tralongo; Paolo Marchetti; Andrea Fontana; Ornella Garrone; null Cazzaniga; null Capici; null Fontana; null Cogliati; null Taverniti; null Schintu; null Ferraù; null Turletti; null Generali; null Di Mauro; null Febbraro; null Marchetti; null Toniolo; null Cazzaniga; null Fontana; null Fontana; null Cretella; null Generali; Antonino Grassadonia; null Vallini; Antonio Febbraro; null Saracchini; Paolo Tralongo; Maria Giuseppina Sarobba; Saverio Cinieri; null Baldelli; null Valenza; Pietro Spadaro; null Leonardi; null Nicolini; Patrizia Vici; Ferdinando Riccardi; Domenico Amoroso; null Cavanna; Lorenzo Gianni; Maria Rosaria Valerio; Antonino Musolino; Valter Torri; null Cazzaniga; Rossana Berardi; Daniele Santini; Samanta Sarti

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

Maria Rosaria Valerio, Vittorio Gebbia, Ciccarese, Clivio, Carlo Putzu, Giovanardi, Cagossi, Gambaro, Scognamiglio, Enrico De Conciliis, Montagna, Vittorio Gebbia, Alfredo Butera, Toniolo, Ferzi, Paolo Tralongo, Paolo Marchetti, Andrea Fontana, Ornella Garrone, CazzanigaCapici, Fontana, Cogliati, Taverniti, Schintu, Ferraù, Turletti, Generali, Di Mauro, Febbraro, Marchetti, Toniolo, Cazzaniga, Fontana, Fontana, Cretella, Generali, Antonino Grassadonia, Vallini, Antonio Febbraro, Saracchini, Paolo Tralongo, Maria Giuseppina Sarobba, Saverio Cinieri, Baldelli, Valenza, Pietro Spadaro, Leonardi, Nicolini, Patrizia Vici, Ferdinando Riccardi, Domenico Amoroso, Cavanna, Lorenzo Gianni, Maria Rosaria Valerio, Antonino Musolino, Valter Torri, Cazzaniga, Rossana Berardi, Daniele Santini, Samanta Sarti

Risultato della ricerca: Article › peer review

1 Citazioni (Scopus)

Abstract

Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting.

Lingua originale	English
pagine (da-a)	1-10
Numero di pagine	10
Rivista	Breast Cancer Research and Treatment
Stato di pubblicazione	Published - 2021

All Science Journal Classification (ASJC) codes

???subjectarea.asjc.2700.2730???
???subjectarea.asjc.1300.1306???

Altri file e collegamenti

OA Link

Cita questo

Valerio, M. R., Gebbia, V., Ciccarese, Clivio, Putzu, C., Giovanardi, Cagossi, Gambaro, Scognamiglio, De Conciliis, E., Montagna, Gebbia, V., Butera, A., Toniolo, Ferzi, Tralongo, P., Marchetti, P., Fontana, A., Garrone, O., ... Sarti, S. (2021). Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Breast Cancer Research and Treatment, 1-10.

Valerio, MR , Gebbia, V, Ciccarese, Clivio, Putzu, C, Giovanardi, Cagossi, Gambaro, Scognamiglio, De Conciliis, E, Montagna, Gebbia, V, Butera, A, Toniolo, Ferzi, Tralongo, P, Marchetti, P, Fontana, A, Garrone, O, Cazzaniga, Capici, Fontana, Cogliati, Taverniti, Schintu, Ferraù, Turletti, Generali, Di Mauro, Febbraro, Marchetti, Toniolo, Cazzaniga, Fontana, Fontana, Cretella, Generali, Grassadonia, A, Vallini, Febbraro, A, Saracchini, Tralongo, P, Sarobba, MG, Cinieri, S, Baldelli, Valenza, Spadaro, P, Leonardi, Nicolini, Vici, P, Riccardi, F, Amoroso, D, Cavanna, Gianni, L, Valerio, MR, Musolino, A, Torri, V, Cazzaniga, Berardi, R, Santini, D & Sarti, S 2021, 'Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study', Breast Cancer Research and Treatment, pagg. 1-10.

@article{c66a5db858944ba39cc4a0443e08ada5,

title = "Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study",

abstract = "Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting.",

author = "Valerio, {Maria Rosaria} and Vittorio Gebbia and Ciccarese and Clivio and Carlo Putzu and Giovanardi and Cagossi and Gambaro and Scognamiglio and {De Conciliis}, Enrico and Montagna and Vittorio Gebbia and Alfredo Butera and Toniolo and Ferzi and Paolo Tralongo and Paolo Marchetti and Andrea Fontana and Ornella Garrone and Cazzaniga and Capici and Fontana and Cogliati and Taverniti and Schintu and Ferra{\`u} and Turletti and Generali and {Di Mauro} and Febbraro and Marchetti and Toniolo and Cazzaniga and Fontana and Fontana and Cretella and Generali and Antonino Grassadonia and Vallini and Antonio Febbraro and Saracchini and Paolo Tralongo and Sarobba, {Maria Giuseppina} and Saverio Cinieri and Baldelli and Valenza and Pietro Spadaro and Leonardi and Nicolini and Patrizia Vici and Ferdinando Riccardi and Domenico Amoroso and Cavanna and Lorenzo Gianni and Valerio, {Maria Rosaria} and Antonino Musolino and Valter Torri and Cazzaniga and Rossana Berardi and Daniele Santini and Samanta Sarti",

year = "2021",

language = "English",

pages = "1--10",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

}

TY - JOUR

T1 - Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

AU - Valerio, Maria Rosaria

AU - Gebbia, Vittorio

AU - Ciccarese, null

AU - Clivio, null

AU - Putzu, Carlo

AU - Giovanardi, null

AU - Cagossi, null

AU - Gambaro, null

AU - Scognamiglio, null

AU - De Conciliis, Enrico

AU - Montagna, null

AU - Gebbia, Vittorio

AU - Butera, Alfredo

AU - Toniolo, null

AU - Ferzi, null

AU - Tralongo, Paolo

AU - Marchetti, Paolo

AU - Fontana, Andrea

AU - Garrone, Ornella

AU - Cazzaniga, null

AU - Capici, null

AU - Fontana, null

AU - Cogliati, null

AU - Taverniti, null

AU - Schintu, null

AU - Ferraù, null

AU - Turletti, null

AU - Generali, null

AU - Di Mauro, null

AU - Febbraro, null

AU - Marchetti, null

AU - Toniolo, null

AU - Cazzaniga, null

AU - Fontana, null

AU - Cretella, null

AU - Generali, null

AU - Grassadonia, Antonino

AU - Vallini, null

AU - Febbraro, Antonio

AU - Saracchini, null

AU - Tralongo, Paolo

AU - Sarobba, Maria Giuseppina

AU - Cinieri, Saverio

AU - Baldelli, null

AU - Valenza, null

AU - Spadaro, Pietro

AU - Leonardi, null

AU - Nicolini, null

AU - Vici, Patrizia

AU - Riccardi, Ferdinando

AU - Amoroso, Domenico

AU - Cavanna, null

AU - Gianni, Lorenzo

AU - Valerio, Maria Rosaria

AU - Musolino, Antonino

AU - Torri, Valter

AU - Cazzaniga, null

AU - Berardi, Rossana

AU - Santini, Daniele

AU - Sarti, Samanta

PY - 2021

Y1 - 2021

N2 - Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting.

AB - Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting.

UR - http://hdl.handle.net/10447/520048

M3 - Article

SN - 0167-6806

SP - 1

EP - 10

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

ER -

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

Abstract

All Science Journal Classification (ASJC) codes

Altri file e collegamenti

Fingerprint

Cita questo